Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 2 of 2 entries
Sorted by: Best Match Show Resources per page
The treatment of chronic hepatitis B: Focus on adefovir-like antivirals.

Therapeutics and clinical risk management

Tillmann HL.
PMID: 19209262
Ther Clin Risk Manag. 2008 Aug;4(4):797-802. doi: 10.2147/tcrm.s1965.

SEVERAL OPTIONS FOR THE TREATMENT OF HEPATITIS B HAVE BEEN LICENSED IN THE LAST YEARS: interferon, pegylated interferon, lamivudine, adefovir, entecavir, and telbivudine. In addition tenofovir has been licensed in the EU and is expected to be licensed in...

Cite
Tillmann HL. The treatment of chronic hepatitis B: Focus on adefovir-like antivirals. Ther Clin Risk Manag. 2008;4(4):797-802doi: 10.2147/tcrm.s1965.
Tillmann, H. L. (2008). The treatment of chronic hepatitis B: Focus on adefovir-like antivirals. Therapeutics and clinical risk management, 4(4), 797-802. https://doi.org/10.2147/tcrm.s1965
Tillmann, Hans Ludger. "The treatment of chronic hepatitis B: Focus on adefovir-like antivirals." Therapeutics and clinical risk management vol. 4,4 (2008): 797-802. doi: https://doi.org/10.2147/tcrm.s1965
Tillmann HL. The treatment of chronic hepatitis B: Focus on adefovir-like antivirals. Ther Clin Risk Manag. 2008 Aug;4(4):797-802. doi: 10.2147/tcrm.s1965. PMID: 19209262; PMCID: PMC2621388.
Copy Download .nbib Format: NLM
Pradefovir Treatment in Patients with Chronic Hepatitis B: Week 24 Results from a Multicenter, Double-blind, Randomized, Noninferiority, Phase 2 Trial.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Gao Y, Kong F, Song X, Shang J, Yao L, Xia J, Peng Y, Liu W, Gong H, Mu M, Cui H, Han T, Chen W, Wu X, Yang Y, Yan X, Jin Z, Wang P, Zhu Q, Chen L, Zhao C, Zhang D, Jin W, Wang D, Wen X, Liu C, Jia J, Mao Q, Ding Y, Jin X, Zhang Z, Mao Q, Li G, Niu J.
PMID: 34487151
Clin Infect Dis. 2021 Sep 06; doi: 10.1093/cid/ciab763. Epub 2021 Sep 06.

OBJECTIVES: Pradefovir is a liver-targeted prodrug of adefovir, a nucleotide analog with antiviral activity against hepatitis B virus (HBV) DNA polymerase. This phase 2 study compared the efficacy and safety of oral pradefovir (30mg, 45mg, 60mg, and 75mg) versus...

Cite
Gao Y, Kong F, Song X, et al. Pradefovir Treatment in Patients with Chronic Hepatitis B: Week 24 Results from a Multicenter, Double-blind, Randomized, Noninferiority, Phase 2 Trial. Clin Infect Dis. 2021;doi: 10.1093/cid/ciab763.
Gao, Y., Kong, F., Song, X., Shang, J., Yao, L., Xia, J., Peng, Y., Liu, W., Gong, H., Mu, M., Cui, H., Han, T., Chen, W., Wu, X., Yang, Y., Yan, X., Jin, Z., Wang, P., Zhu, Q., Chen, L., Zhao, C., Zhang, D., Jin, W., Wang, D., Wen, X., Liu, C., Jia, J., Mao, Q., Ding, Y., Jin, X., Zhang, Z., Mao, Q., Li, G., & Niu, J. (2021). Pradefovir Treatment in Patients with Chronic Hepatitis B: Week 24 Results from a Multicenter, Double-blind, Randomized, Noninferiority, Phase 2 Trial. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, . https://doi.org/10.1093/cid/ciab763
Gao, Yanhang, et al. "Pradefovir Treatment in Patients with Chronic Hepatitis B: Week 24 Results from a Multicenter, Double-blind, Randomized, Noninferiority, Phase 2 Trial." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America vol. (2021). doi: https://doi.org/10.1093/cid/ciab763
Gao Y, Kong F, Song X, Shang J, Yao L, Xia J, Peng Y, Liu W, Gong H, Mu M, Cui H, Han T, Chen W, Wu X, Yang Y, Yan X, Jin Z, Wang P, Zhu Q, Chen L, Zhao C, Zhang D, Jin W, Wang D, Wen X, Liu C, Jia J, Mao Q, Ding Y, Jin X, Zhang Z, Mao Q, Li G, Niu J. Pradefovir Treatment in Patients with Chronic Hepatitis B: Week 24 Results from a Multicenter, Double-blind, Randomized, Noninferiority, Phase 2 Trial. Clin Infect Dis. 2021 Sep 06; doi: 10.1093/cid/ciab763. Epub 2021 Sep 06. PMID: 34487151.
Copy Download .nbib Format: NLM
Showing 1 to 2 of 2 entries